
FDA Approvals
Tracks the openFDA Drugs@FDA feed for AP (approved) submissions from a curated set of large, US-listed pharma and biotech sponsors (Eli Lilly, Pfizer, Merck, AbbVie, Bristol Myers, Amgen, Gilead, Vertex, Regeneron, Biogen, Moderna, Novartis, AstraZeneca, GSK, J&J, Novo Nordisk, Sanofi, Takeda, BioMarin, Alnylam, Jazz, Incyte, Exelixis, Halozyme, United Therapeutics, Neurocrine). Emits a long-bias trade_card for the sponsor's ticker on each new approval. Original approvals (ORIG) score higher than supplemental ones (SUPPL). Every sponsor ticker is verified present in the tradeable universe — never a fabricated mapping.
Verified performance
66.7%–90.0% 95% CI
Last 50 signals
An FDA approval unlocks a drug's commercial path — for a pharma or biotech name it can be the single most important catalyst there is, and it's a matter of public record the moment it posts.